LONG-TERM HEPATOPROTECTIVE EFFECTS OF GLP-1RA IN OBESE PATIENTS WITH TYPE 2 DIABETES: A RETROSPECTIVE COHORT STUDY

被引：0
|
作者：
Khataniar, Himsikhar [1 ]
Dharia, Ashni [1 ]
Desai, Aakash [2 ]
Butt, Muhammad Ali [1 ]
Babich, Michael [1 ]
Mohy-ud-din, Nabeeha [1 ]
机构：
[1] Allegheny Gen Hosp, Pittsburgh, PA USA
[2] Mayo Clin Jacksonville, Jacksonville, FL USA
来源：
HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1625
引用
收藏
页数：2
相关论文
共 50 条
  • [41] GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes
    Park, Brady
    Krishnaraj, Aishwarya
    Teoh, Hwee
    Bakbak, Ehab
    Dennis, Fallon
    Quan, Adrian
    Hess, David A.
    Verma, Subodh
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2024, 327 (02): : H370 - H376
  • [42] CGM Use in People with Type 2 Diabetes Initiating GLP-1 or GIP/GLP-1RA Therapy-Real-World Data
    Wang, Xiaohan
    Xu, Ying
    Norman, Gregory J.
    Reid, Jennifer L.
    Singh, Harsimran
    Yang, Lei
    DIABETES, 2024, 73
  • [43] Treatment Trends in Youth-Onset Type 2 Diabetes: Changing Landscape After GLP-1RA Approval
    Shin, Hojin
    Paik, Julie M.
    Wexler, Deborah J.
    Patorno, Elisabetta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 583 - 583
  • [44] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Hiep Nguyen
    Robert Dufour
    Amanda Caldwell-Tarr
    Advances in Therapy, 2017, 34 : 658 - 673
  • [45] Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population
    Nguyen, Hiep
    Dufour, Robert
    Caldwell-Tarr, Amanda
    ADVANCES IN THERAPY, 2017, 34 (03) : 658 - 673
  • [46] What are the early metabolic effects of combining duodenal exclusion and glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy in patients with Type 2 diabetes?
    Sen Gupta, P.
    Amiel, S. A.
    McGowan, B. M.
    Drummond, R. S.
    Bajwa, R. S.
    Blann, A. D.
    Ryder, R. E. J.
    DIABETIC MEDICINE, 2015, 32 : 98 - 98
  • [47] Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages
    Koike, Masao
    Saito, Hitoki
    Kohno, Genta
    Takubo, Masahiro
    Watanabe, Kentaro
    Ishihara, Hisamitsu
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [48] Invited review. Series: Implications of the recent CVOTs in type 2 diabetes Which patients for GLP-1RA or SGLT-2 inhibitor?
    Dardano, Angela
    Miccoli, Roberto
    Bianchi, Cristina
    Daniele, Giuseppe
    Del Prato, Stefano
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2020, 162
  • [49] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    Meiring, S.
    Busch, C. B. E.
    van Baar, A. C. G.
    Hemke, R.
    Holleman, F.
    Nieuwdorp, M.
    Bergman, J. J. G. H. M.
    CARDIOVASCULAR DIABETOLOGY, 2022, 21 (01)
  • [50] Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1RA decreases risk scores for cardiovascular events
    S. Meiring
    C. B. E. Busch
    A. C. G. van Baar
    R. Hemke
    F. Holleman
    M. Nieuwdorp
    J. J. G. H. M. Bergman
    Cardiovascular Diabetology, 21
12345